"Arctic blast" yields better lyophilisation results
Users of LyoSpeed on Series 3 HT Evaporators report a greater percentage of samples yield dry powders than they have previously been able to achieve.
Benefiting from a state-of-the-art -75 °C condenser - the Series 3 HT Evaporator from Genevac sets a new benchmark for enhanced evaporation and lyophilisation results.
Drying HPLC purification fractions, such as water and acetonitrile, is a routine yet essential task in many pharmaceutical laboratories. Typically labs require HPLC fractions to be dried to a powder form, such that samples can be accurately weighed, easily sub-sampled and re-dissolved. To provide a rapid, high-throughput alternative to freeze drying of such samples, Genevac developed its proprietary fast lyophilisation (LyoSpeed) methodology for use on their HT Series Evaporators. While the LyoSpeed has traditionally worked well for hydrophilic samples, difficulties may arise when the samples do not readily dissolve in only water.
The Series 3 HT Evaporator features an integral -75 °C condenser as standard. Operating at higher power than any other commercially available condenser, users of LyoSpeed on Series 3 HT Evaporators have reported that a greater percentage of samples yield dry powders than they have previously been able to achieve.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.